Abstract
Sulphonylureas (SUs) offer effective glycemic control; however, they are generally not recommended anymore due to concerns about cardiovascular (CV) safety, despite absence of a CV safety outcome trial (CVOT). CAROLINA – a randomized noninferiority CVOT concluded a comparable CV safety of linagliptin (a dipeptidyl peptidase 4 inhibitor [DPP4I]) and glimepiride (a SU). We synthesized similar CVOTs and indirectly compared the effect of glimepiride vs placebo, and DPP4Is on major CV safety outcomes.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
